Nuclei Isolation from Fresh Frozen Brain Tumors for Single-Nucleus RNA-seq and ATAC-seq
August 25th, 2020
12.8K views
Intra-tumoral heterogeneity is an inherent feature of tumors, including gliomas. We developed a simple and efficient protocol that utilizes a combination of buffers and gradient centrifugation to isolate single nuclei from fresh frozen glioma tissues for single nucleus RNA and ATAC sequencing studies.
Overview
This study presents a simple and efficient protocol for isolating single nuclei from fresh frozen glioma tissues. The method is designed for single nucleus RNA and ATAC sequencing studies, addressing intra-tumoral heterogeneity in gliomas.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Genomics
Background
- Intra-tumoral heterogeneity is a common feature of tumors.
- Understanding tumor evolution and therapy effects is crucial for treatment.
- High-quality nuclei isolation is essential for accurate analysis.
- Archival frozen tumors can also be utilized with this method.
Purpose of Study
- To isolate nuclei from fresh frozen tumors for research.
- To facilitate transcriptional and epigenetic studies.
- To explore tumor evolution and response to therapies.
Methods Used
- Combination of buffers and gradient centrifugation.
- Isolation of single nuclei from glioma tissues.
- No sorting step to minimize stress on nuclei.
- Applicable to both fresh and archival frozen tumors.
Main Results
- The method yields high-quality nuclei suitable for sequencing.
- Processing time is significantly reduced.
- Demonstrated by Ashwin Narayanan, a postdoctoral fellow.
- Supports multiple downstream applications in tumor research.
Conclusions
- The protocol is effective for studying glioma heterogeneity.
- It enhances the understanding of tumor dynamics.
- Provides a reliable tool for future research in oncology.
Frequently Asked Questions
What is the main advantage of this method?
The method is simple, reduces processing time, and yields high-quality nuclei.
Can this method be used on archival samples?
Yes, the protocol is applicable to archival frozen tumors.
Who demonstrated the procedure?
Ashwin Narayanan, a postdoctoral fellow, demonstrated the procedure.
What types of studies can this method support?
It supports transcriptional and epigenetic studies of tumors.
How does this method affect the nuclei?
The absence of a sorting step reduces stress on the nuclei.
What are the implications of this research?
It enhances understanding of tumor evolution and therapy effects.
Executive Industry Relevance
Isolating high-quality nuclei from archival frozen brain tumor samples enables scalable multi-omics analysis without fresh tissue constraints. This approach supports target validation and mechanistic de-risking in glioma drug discovery by providing reproducible molecular profiles from biobanked specimens. The method reduces processing time and technical variability, accelerating preclinical target characterization.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of tumor heterogeneity and clonal evolution from archival specimens.
- Operational Value: Eliminates need for fresh tissue processing, increasing sample throughput and biobank utilization.
- Predictive Value: Provides matched epigenomic and transcriptomic data for de-risking therapeutic targets.
Screening & Assay Development
- Scientific Value: Generates standardized nuclei suspensions suitable for high-throughput snRNA-seq and snATAC-seq platforms.
- Operational Value: Uses gradient centrifugation and filtration to remove debris, ensuring assay-ready inputs.
- Scalability: Compatible with 10x Genomics and similar microfluidic systems for large-scale screening.
Translational & Preclinical Research
- Translational Continuity: Links discovery-phase molecular profiling to preclinical models using consistent sample preparation.
- Mechanistic De-risking: Enables co-embedding of chromatin accessibility and gene expression data to clarify regulatory mechanisms.
- Predictive Confidence: Supports biomarker-aligned target prioritization through multi-omics concordance.
Pipeline & Workflow Integration
The method fits within the discovery-to-preclinical continuum by providing a standardized input for multi-omic profiling of brain tumors.
- Discovery Biology: Supports hypothesis testing on tumor evolution and therapy response using archival cohorts.
- Screening: Delivers quantitative, reproducible nuclei yields for downstream sequencing applications.
- Analytics: Enables UMI and gene distribution analysis for quality control and cross-study comparison.
- Translational Research: Facilitates biomarker alignment through matched snRNA-seq and snATAC-seq from the same nuclei.
- Enterprise Reuse: Establishes a reusable nuclei isolation workflow for frozen tumor biobanks across oncology projects.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity by linking chromatin state to transcriptional output in glioma.
- Operational Value: Standardizes nuclei isolation across sites, improving reproducibility and reducing pre-analytical variance.
- Strategic Value: Increases capital efficiency by enabling retrospective analysis of archival tumor collections.
- Portfolio Impact: Supports risk-adjusted target selection through multi-omic validation from preserved specimens.
Implementation Considerations
- Requires expertise in tissue homogenization and gradient centrifugation techniques.
- Dependent on access to swinging bucket centrifuges and iodixanol gradient preparation.
- Necessitates standardized filtration and staining protocols for nuclei quantification.
- Adaptation may be needed for non-glioma tumor types based on lysis buffer optimization.
- Practical limitation: Gradient purity depends on careful layer separation to avoid contamination.
Biopharma FAQs
Why does nuclei isolation from frozen tissue matter for target validation?
It enables molecular profiling of archival tumor samples, supporting retrospective target validation without fresh tissue constraints. This increases access to clinically annotated specimens for de-risking therapeutic hypotheses. The method yields nuclei suitable for both RNA and chromatin analysis from the same preparation.
How does gradient centrifugation improve nuclei purity for downstream applications?
The iodixanol gradient centrifugation step separates nuclei from debris and cellular contaminants based on density. A clear white band at the interface indicates high-purity nuclei recovery. This reduces background noise in snRNA-seq and snATAC-seq data, improving signal detection.
What quantitative measurements enable nuclei quality assessment?
Nuclei are quantified using Trypan Blue staining and hemocytometer counting to determine yield and viability. Microscopic verification ensures intact nuclear membranes and absence of distortion. These metrics confirm suitability for single-nucleus sequencing platforms.
Why are replication requirements important for cross-functional collaboration?
Standardized nuclei isolation protocols ensure consistent input quality across sites and teams. Reproducible yields and purity levels enable reliable comparison of multi-omics data from different laboratories. This supports collaborative target validation efforts using shared biobank resources.
What statistical analysis capabilities are required before implementing this method?
Teams must be able to compare UMI and gene distribution profiles against reference datasets using violin plots or similar visualizations. This enables assessment of protocol performance relative to published snRNA-seq methods. Such analysis confirms data comparability and quality before scaling to discovery projects.
